Delighted to be working with ARPA-H within the POSEIDON program - something that really has the chance to transform cancer detection using a test with only breath and urine samples, to be performed in the home. This award further validates Owlstone Medical's leading position in the breath space, and is the result of some very hard work from our internal experts. I was honoured to visit the Walter Reed National Military Medical Center last week to kick this program off with our collaborators, and hope that this proves to be the ground-breaking initiative that it sets out to be.
📣 We are excited to announce that Owlstone Medical has been awarded up to $49.1M from ARPA-H for our project within the POSEIDON program, a groundbreaking initiative to develop the first at-home multi-cancer early detection test (MCED). Throughout this program, we are proud to collaborate with Massachusetts Institute of Technology, Boston University, Georgia Tech Research, Qurin, and Planned Systems International. Why does it matter? Nearly 40% of Americans will face cancer in their lifetime. Detecting it early not only saves lives but could also reduce healthcare costs by trillions of dollars. Learn more about this development in our latest press release 👉 https://bit.ly/4nvM7YW #CancerDetection #HealthcareInnovation #EarlyDetection
Congrats Team Owlstone
Well done!!!
Congratulations Owlstone Medical, exciting to see. 👏
Great stuff Neil, Billy and team Owlstone Medical 👏🏼👏🏼👏🏼